CCEL Stock Risk & Deep Value Analysis
Cryo-Cell International Inc
DVR Score
out of 10
The Bottom Line on CCEL
We analyzed Cryo-Cell International Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran CCEL through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
Get notified when CCEL moves
Same alert types as Telegram — presets or custom thresholds in your 🔔 feed.
📈CCEL Performance Overview3yr weekly
Unlock CCEL Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
CCEL Quality Rating
CCEL Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
High
CCEL Deep Value Analysis
CCEL Research Sources
No external source links for this analysis yet. Run a fresh analysis to capture SEC filings and financial news articles we used.
For educational context only. Not financial advice.
CCEL Red Flags & Warning Signs
- ⚠
NYSE American delisting due to noncompliance
- ⚠
Failure to secure sufficient capital, leading to further financial deterioration or insolvency
Unlock CCEL Red Flags & Risk Warnings
Premium members see every risk event we found.
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
Unlock everything for $47/yr
$79/yrSave 41%
- ✓ Catalysts, bull case, moat & red flags
- ✓ Unlimited stock analyses + alerts
- ✓ Full database, search & portfolio (50 stocks)
7-day money back · Cancel anytime
CCEL Financial Health Metrics
Market Cap
$36.67M
P/E Ratio
-64.99
Profit Margin
-1.49%
Debt-to-Equity
0.00
Dividend Yield
0.00%
Beta (Volatility)
0.00
Earnings Per Share
$-1.06
CCEL Competitive Moat Analysis
Moat Rating
Narrow
Moat Trend
Eroding
Moat Sources
2 Identified
Highly fragile. While historical brand recognition and operational expertise exist in cord blood banking, the severe financial distress and lack of capital for aggressive cell therapy expansion severely compromises the moat's durability against well-funded, innovative competitors in the rapidly evolving biotech landscape.
CCEL Competitive Moat Analysis
Premium unlocks moat rating, sources & durability.
CCEL Catalysts & Growth Drivers
Near-Term (0-6 months)
- •NYSE American compliance plan decision (post-April 8, 2026 submission deadline)
- •Securing new, significant financing to address liquidity and stockholders' deficit
Medium-Term (6-18 months)
- •Stabilization and growth of core cord blood banking business
- •Announcement of a new, substantial partnership or milestone in cell therapy development
Long-Term (18+ months)
- •Successful commercialization of a proprietary cell therapy product
- •Return to sustained profitability and positive cash flow generation
Catalysts & Growth Drivers
Sign up free to see growth catalysts
CCEL Bull Case: What Could Go Right
- ✓
Positive resolution of the NYSE American noncompliance issue (approval of compliance plan)
- ✓
Announcement of substantial new capital injection or strategic partnership for cell therapy
- ✓
Clear evidence of declining net losses and progress towards cash flow positivity
Bull Case Analysis
Sign up free to see the bull case
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
FAQ
What is the DVR Score for Cryo-Cell International Inc (CCEL)?
As of April 9, 2026, Cryo-Cell International Inc has a DVR Score of 1.2 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Cryo-Cell International Inc?
Cryo-Cell International Inc's market capitalization is approximately $36.7M..
What is the risk level for CCEL stock?
Our analysis rates Cryo-Cell International Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of CCEL?
Cryo-Cell International Inc currently has a price-to-earnings (P/E) ratio of -65.0. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Cryo-Cell International Inc's revenue growing?
Cryo-Cell International Inc has reported revenue growth of -1.3%. Revenue has been declining, which warrants closer examination.
Is CCEL stock profitable?
Cryo-Cell International Inc has a profit margin of -1.5%. The company is currently unprofitable.
How often is the CCEL DVR analysis updated?
Our AI-powered analysis of Cryo-Cell International Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 9, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.